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Abstract
The non-classical MHC I paralogue HLA-G is expressed by cytotrophoblast cells and impli-
cated with fetomaternal tolerance by downregulating the maternal adaptive and innate
immune response against the fetus. HLA-G expression correlates with favorable graft out-
come in humans and recently promising immunosuppressive effects of therapeutic HLA-G
in experimental transplantation (skin allograft acceptance) were shown. Consequently, we
examined this novel therapeutic approach in solid organ transplantation. In this study, thera-
peutic recombinant HLA-G5 was evaluated for the first time in a solid organ model of acute
rejection (ACR) after orthotopic intestinal transplantation (ITX). Allogenic ITX was per-
formed in rats (Brown Norway to Lewis) with and without HLA-G treatment. It was found that
HLA-G treatment significantly reduced histologically proven ACR at both an early and late
postoperative timepoint (POD 4/7), concomitant to a functionally preserved graft contractility
at POD 7. Interestingly, graft infiltration by myeloperoxidase+ cells was significantly reduced
at POD7 by HLA-G treatment. Moreover, HLA-G treatment showed an effect on the allo-
genic T-cell immune response as assessed by flow cytometry: The influx of recipient-
derived CD8+ T-cells into the graft mesenteric lymphnodes at POD7 was significantly
reduced while CD4+ populations were not affected. As a potential mechanism of action, an
induction of T-reg populations in the mesenteric lymphnodes was postulated, but flow cyto-
metric analysis of classical CD4+/CD25+/FoxP3+Treg-cells showed no significant alteration
by HLA-G treatment. The novel therapeutic approach using recombinant HLA-G5 reported
herein demonstrates a significant immunosuppressive effect in this model of allogenic
experimental intestinal transplantation. This effect may be mediated via inhibition of recipi-
ent-derived CD8+ T-cell populations either directly or by induction of non-classical Treg
populations.
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Introduction
In intestinal transplantation, episodes of ACR are frequent and impact severely on patient sur-
vival and outcome. While ACR may be treated by intensifying baseline immunosuppression
and administration of pulsed steroids, concomitant systemic inflammatory response and sepsis
due to compromised intestinal barrier function under increased immunosuppression increases
mortality. In the past, attempts to achieve functional (or “prope”) tolerance in intestinal trans-
plantation to minimize potentially harmful over-immunosupression and improve long-term
outcome by avoiding chronic rejection have not been successful. Historic strategies, like the
enhancement of bone-marrow chimerism or the depletion of passenger lymphocytes via graft
irradiation, were abandoned after initial enthusiasm [1,2]. Meanwhile, induction therapy with
depleting antibodies, calcineurin-inhibitors and steroids have become the workhorse in intesti-
nal transplantation with excellent short and midterm outcome in specialized centers [2]. Nev-
ertheless, this approach has failed to achieve “prope tolerance”, even though some patients can
be successfully weaned to very low doses of immunosupression without developing rejection
[2,3]. Chronic graft dysfunction (observed in up to 20% of patients) remains the major obstacle
of intestinal transplantation and new tolerogenic strategies are needed where conventional
immunosuppression has failed. Therefore, a new strategy to counteract rejection after intestinal
transplantation was tested in this study. The non-classical MHC I paralogue HLA-G has been
implicated with a central role in fetomaternal tolerance and could be a promising potential can-
didate for tolerogenic protocols in solid organ transplantation [4]. Expressed mainly–but not
exclusively- by the human cytotrophoblast, it partakes in the protection of the fetus (e.g. a
semi-allogenic allograft) from the mother’s immune system via downregulating adaptive (T
cell) and innate (NK cell) immunity [5,6]. The observation that HLA-G was expressed on
immunoprivileged tissues [7,8] and could effectively downregulate T- and NK-cell immune
responses as well as DC maturation in vitro [9,10], has stimulated transplant-related research:
Higher HLA-G expression levels in heart, liver, kidney and lung transplant recipients corre-
lated with favorable outcome and fewer rejection episodes [11,12]. While this approach hinted
at involvement of endogenous HLA-G expression in transplant-patient subgroups with favor-
able outcome, it did not test the efficacy of HLA-G as a potential therapeutic agent to counter-
act allograft rejection. Recently, promising studies have shown tolerogenic effects of exogenic
HLA-G when used as a therapeutic immunomodulant in dimeric form allowing application in
experimental transplantation. Favier et al. have demonstrated skin allograft acceptance in mice
after intraperitoneal administration of HLA-G coated polystyrene beads [13]. Because of the
known mechanisms of action of HLA-G (e.g. blunting the CD8+ T-cell response or inducing
tolerogenic regulatory T-cells [14]), it was hypothesized that soluble HLA-G would exhibit
similar tolerogenic properties in experimental intestinal transplantation. Thus, in this study,
HLA-G was evaluated in experimental intestinal transplantation—a solid organ especially
prone to acute and chronic rejection.
Material and Methods
Study design
To study the therapeutic potential of recombinant HLA-G to prevent rejection of intestinal
grafts, orthotopic allogenic ITX (Brown Norway (BN) to Lewis (LEW)) was performed in 4
groups (n = 5 rats each) using a standardized technique with end-to-side aorto-aortic and
porto-caval microvascular anastomoses and reestablishment of enteral continuity. A cold and
warm ischemia time of 60 and 30 minutes respectively was maintained during the operative
procedure and University of Wisconsin solution was used for organ preservation during cold
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ischemia, as previously described [15]. The high responder strain combination (BN->LEW) is
known to exhibit severe ACR after 4–7 days without immunosuppression after intestinal trans-
plantation, and accordingly these time points were chosen for evaluation of ACR as optimal to
detect the postulated immunosuppressive effect [16]. For the study, the two groups of recipient
animals (LEW) received 10 million of HLA-G coated polystyrene beads i.p. at 24h hours prior
to and upon completion of the transplant procedure (see Fig 1). The control groups received
the same amount of blank polystyrene beads without prior HLA-G loading. The animals were
then observed for four or seven days before sacrifice and assessment of ACR. Survival experi-
ments where not planned or performed due to german animal protection regulations. For a
synopsis of the experimental design and groups see Fig 1.
Animals
Inbred male LEW and BN rats weighing 180–200 g were obtained from Charles River WIGA
GmbH (Sulzfeld, Germany). All experiments were performed in accordance with the european
and german federal law regarding the protection of animals with prior approval by the Lande-
sumweltamt and principles of laboratory animal care (NIH Publication No.8 5–23, revised
1985) were followed. All surgery was performed under isoflurane inhalation anesthesia with
additional carprofen analgesia (5mg /kg s.c for 3 days), and all efforts were made to minimize
suffering. Animals were kept at the facility for seven days prior to the procedure for acclimati-
zation and maintained on a 12-h light/dark cycle and provided with commercially available
chow (Altromin, Lage, Germany) and tap water ad libitum, respectively. At the end of the
respective observation periods animals were euthanized under general anesthesia with isoflur-
ane overdose and exsanguination during organ procurement.
Immunoprecipitation of HLA-G / HLA-G beads
Cell supernatant containing HLA-G, or more specifically, the ß2-microglobulin fused to the
HLA-G5 heavy chain (referred to as B2M-HLA-G5), was generously supplied from Dr. Le
Maoult's group and coated on 4.5μm polystyrene beads (Polysciences Inc., Eppelheim, Ger-
many) as previously described [13]: In short, the polystyrene beads were first incubated with
Fig 1. Experimental groups and study design.
doi:10.1371/journal.pone.0158907.g001
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anti-HLA-G antibody 5A6 (Exbio, Praha) overnight in 0.1 M borate buffer. In a second step,
the antibody-coated beads where used for immunoprecipitation of B2M-HLA-G5 from the
previously mentioned cell supernatant. A western blot using the diagnostic anti-HLA-G anti-
body clone 4H84 (Exbio, Praha) confirmed loading of the beads with the fusion protein. Con-
trol beads were prepared in the same manner using PBS instead of cell supernatant containing
B2M-HLA-G5.
Flow cytometric analysis
Graft draining lymphnodes were sampled and analyzed by flow cytometry using a BDCAN-
TOII flow cytometer (BD Franklin Lakes, New Jersey USA) after lymphocyte isolation. Anti-
bodies used for FACS-staining for T-cell analysis were biotinylated anti-rat CD45 (Biolegend,
San Diego, USA) with secondary streptavidin-Pacific Blue (Life Technologies, Darmstadt, Ger-
many), anti-rat CD4 PerCP-eFluor 710 (eBioscience, San Diego, USA) and anti-rat CD8 APC
(eBioscience, San Diego, USA). To distinguish between recipient (LEW) and donor (BN)
derived T-lymphocytes (i.e “passenger lymphocytes”), a monoclonal anti-rat MHC class I anti-
body (specific for BNMHC class I haplotype “c”, RT1.Ac, AbD Serotec), was used. Antibodies
used for analysis of Treg were anti-rat CD45 and anti-rat CD4 as above, followed by anti-rat
CD25 APC (eBioscience, San Diego USA) and anti-FoxP3 FITC (eBioscience, San Diego USA)
using the FoxP3 staining buffer set (eBioscience, San Diego USA) according to manufacturer’s
description. Samples were evaluated using a standardized gating strategy with FlowJo Version
10 (Treestar Inc., Ashland USA). For analysis, relative T cell proportions are given as percent-
ages of the respective CD45+ parent population. This strategy, with CD45+ primary staining as
a pan-leucocytic marker was chosen to ensure comparability of the results, despite possible var-
iation in efficiency of leucocyte isolation.
Real time quantitative PCR
For the gene expression analysis, several known ACR-related markers were chosen. Our group
has shown previously that TNFα, IFNγ, ICAM-1, IL-10, IL-6 overexpression in the tunica mus-
cularis is associated with ACR in this model of orthotopic allogenic intestinal transplantation
[17]. For the expression analyses, mRNA was isolated from sampled mid-jejunal graft muscu-
laris (RNeasy kit, Qiagen, Hilden,Germany), transcribed to cDNA (HighCapacity cDNA
reverse transcription, Life Technologies, Darmstadt, Germany) using kits according to manu-
facturer’s instructions and measured on a Taqman cycler (7900 HT, Life Technologies, Darm-
stadt, Germany) for real-time PCR. For the evaluated cytokines (TNFα, IFNγ, ICAM-1, IL-10,
IL-6), FAM-labeled probes were obtained (Life Technologies, Darmstadt) and the housekeep-
ing gene GapDH was used for normalization. To establish the presence of the PIR-B receptor
(Lilrb3/NILR-1, Entrez Gene ID 65146) in the graft mesenteric lymphnodes (gMLN) in our
model, RT-PCR was likewise performed with a specific FAM-labeled probe against the respec-
tive mRNA with a 77bp amplicon (Thermofisher Scientific Assay No: RN00581823). The pres-
ence of the specific amplicon was confirmed by gel staining (see S2 Fig).
Statistics
Data was analyzed with GraphPad Prism 5.04 (La Jolla, USA). After testing for normal distri-
bution using the D’Agostino and Pearson’s tests, the appropriate methods of analysis were
determined. For non-normally distributed data, non-parametric testing (Mann-Whitney U /
Kruskal-Wallis test) followed by Dunn’s multiple comparison’s test was employed. For nor-
mally distributed data, student’s t-test or one-way ANOVA was performed. P values< 0.05
were considered significant. Interrater reliability of histopathologic assessment was confirmed
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using Cohen’s κ. As described by Landis and Koch 1977, Cohen’s κ was interpreted as “slight
agreement” for the range of 0–0.20, “fair agreement” for the range of 0.21–0.40, “moderate
agreement” for the range of 0.41–0.60 and “substantial agreement” for the range of κ = 0.61–
0.80 [18]. Smooth muscle contractility, as measured in a dose-response curve using the musca-
rinic agonist betanechol in a standard organ bath, was compared by fitting the normalized data
to a logistic curve (four-parameter sigmoidal model) and comparing the fitted midpoint
(logEC50) and slope, using the F test and Graph Pad Prism 5.04. All data relevant to reach the
conclusions drawn in the manuscript with related metadata and methods, and any additional
data required to replicate the reported study findings in their entirety is found in the manu-
script and supporting information files.
Results
Assessment of acute rejection by histology (Wu-score)
Multiple formalin-fixed and paraffin-embedded graft sections of the mid-jejunum were
obtained and stained with hematoxylin-eosin for histological grading. Specimens were blinded
and graded for ACR by two independent reviewers (MW and ML) using the Wu score and
standardized score sheets [19]. Interrater reliability of histopathologic assessment was con-
firmed using Cohen’s κ. At both time points (four and seven days), HLA-G treatment showed
a significant reduction in ACR severity as assessed by the two independent reviewers. (CTL 4d
vs. HLA-G 4d and CTL 7d vs. HLA-G 7d, Mann-Whitney U test: p<0.05, respectively). The
interrater reliability showed a moderate agreement (Cohen’s κ = 0.57), see Fig 2A/2B. The
increased rate of epithelial apoptosis associated with rejection, which was ameliorated by
HLA-G treatment, was confirmed using TdT-mediated dUTP-biotin nick end labeling at
POD7 (TUNEL, see S1 Fig).
Myeloperoxidase-staining in graft muscularis whole-mounts by Hanker-
Yates reaction
To assess monocytic/granulocytic graft infiltration, graft muscularis whole mounts were freshly
prepared from ileal segments by mechanical separation of the mucosa from the graft muscu-
laris, fixing the tissue with 100% EtOH and staining the samples with Hanker-Yates reagent to
visualize myeloperoxidase+-cell populations as described in [20]. Whole mounts were then
analysed under a Nikon TE2000-E microscope, for the evaluation of myeloperoxidase+-cells,
five fields of view (magnification 100x) were randomly chosen for cell count. The intestinal
grafts showed a significantly reduced infiltration by MPO+ cells after HLA-G treatment at
seven days after allogenic ITX compared to untreated controls (CTL 7d vs. HLA-G 7d, Mann-
Whitney U test: p<0.05), see Fig 3. At the earlier timepoint of four days, MPO+ cell infiltration
in the grafts did not differ between groups.
In-vitro contractility measurements of isolated graft muscularis strips
As a functional parameter for ACR-induced graft damage, in-vitro contractility of isolated
muscularis strips in a standardized organ bath (oxygenated KRBS buffer) was analyzed by gen-
erating a dose-response curve using the muscarinic agonist betanechol in rising concentrations
[3x10-4M—0,3M betanechol], as described in [20]. The inducible contractile force of separated
graft muscularis strips is known to correlate with severity of ACR and structural integrity of
the intestinal grafts [21]. In this case, betanechol-induced contractile force showed no differ-
ence at 4 days after transplantation with or without HLA-G treatment. However, at 7 days, a
significantly ameliorated graft contractility with HLA-G treatment was observed (see Fig 4).
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Fig 2. Morphologic characteristics and histologic grading of ACR using theWu-score. (A) Representative H/E stained intestinal
specimens with and without HLA-G treatment. Arrows indicate stronger leucocytic infiltration in graft mesentery, sites of crypt epithelial
injury, propria fibrosis and increased crypt apoptotic body counts, respectively. (B) Overview of severity of ACR as assessed byWu-score
(one reviewer shown). n = 5 in each group.
doi:10.1371/journal.pone.0158907.g002
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After fitting the normalized data to a logistic curve as described above, the fitted midpoints
(logEC50)/slopes were calculated and compared: logEC50 CTL 4d: -1.61 vs. logEC50 HLA-G 4d
-1.69 (ns) and slope CTL 4d: 0.44 vs. HLA-G 4d: 0.44 (ns) or logEC50 CTL 7d: -0.41 vs.
logEC50 HLA-G 7d -1.5 (significant, F test< 0.001) and slopes CTL 7d: 0.41 vs. HLA-G 7d:
0.76 (significant, F test< 0.001).
Flow cytometric analysis
After lymphocyte isolation fom the graft draining lymphnodes (gMLN), flow cytometric analy-
sis was performed to assess the allogenic T-cell response and possible modulation by HLA-G
treatment. Relative T-cell proportions of recipient-derived CD4+ and CD8+ are reported as
percentages of the respective CD45+ parent population to allow individual comparison. At
postoperative day four, no significant changes in either CD4+ or CD8+ cell infiltration of
gMLN were observed with or without HLA-G treatment. At postoperative day seven however,
ACR caused a significant rise in CD8+ cell infiltration in the CTL group versus the earlier time-
point of four days (CTL 4d vs. CTL 7d Mann-Whitney U test: p<0.05). Furthermore, this
recipient-derived CD8+ cell infiltration in the gMLN was significantly reduced by HLA-G
treatment compared to control (CTL 7d vs. HLA-G 7d, Mann-Whitney U test: p<0.05 (see Fig
5A/5B). This reduction of CD8+ cell infiltration was observed concomitantly to significantly
Fig 3. MPO+ cells in graft muscularis whole-mounts stained by Hanker-Yates reaction. At seven days after ITX, HLA-G treatment caused a
significant reduction in MPO+ cell infiltrate in the graft muscularis.
doi:10.1371/journal.pone.0158907.g003
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ameliorated ACR in these grafts. Classical regulatory T-cells (CD4+/CD25+/FoxP3+ Treg), iso-
lated from graft draining lymphnodes, showed a tendency to higher abundance in HLA-G
treated animals, without reaching statistical significance (Fig 6, Mann-Whitney U test p>0.05).
Real time quantitative PCR
To objectively assess the degree of molecular inflammation in the graft muscularis, qPCR
based gene expression analysis of known ACR-related markers (TNFα, IFNγ, ICAM-1, IL-10
and IL-6) in graft muscularis samples was performed. Separated graft muscularis was obtained,
snap-frozen immediatly in liquid nitrogen after organ harvest as described before, and mRNA
was isolated and transcribed to cDNA using the commercially available kits mentioned above
(Quiagen, Germany). The first time point four days after allogenic ITX showed a significant
downregulation of both TNFα and IL-10 by HLA-G treatment (Mann-Whitney U test
p<0.05). At seven days after allogenic ITX, TNFα expression remained significantly reduced
by HLA-G treatment (see Fig 7). The presence of the Pir-B receptor (Lilrb3/NILR-1, Entrez
Gene ID 65146) in the gMLN was confirmed using a specific FAM-labeled PCR probe as
described above. The presence of the specific 77bp amplicon spanning an exon juction was
confirmed in 4 different animals (triplicate detection) by gel staining (see S2 Fig), as previously
described [36].
Discussion
In this study, the immunosuppressive potential of recombinant HLA-G in the treatment of
ACR after allogenic intestinal transplantation was demonstrated histologically and function-
ally. On the cellular level, a significantly reduced and ACR-related MPO+ -cell infiltration into
the graft muscular layer and a reduced influx of recipient-derived CD8+ T-cells into the graft
draining mesenteric lymphnodes were found as potential mechanisms of action. A relevant
induction of classical CD4+/CD25+/FoxP3+ regulatory T-cells in the gMLN by HLA-G treat-
ment could not be proven.
Fig 4. In-vitro graft contractility measured as a dose-response curve under betanechol stimulation. Dose response of graft contractility to rising
bethanechol concentrations, curves fitted to a logistic four-parameter sigmoidal model. Both midpoint (logEC50) and slope were significantly ameliorated
by HLA-G treatment at seven days after ITX.
doi:10.1371/journal.pone.0158907.g004
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Fig 5. Gating strategy and overview of CD4+ and CD8+ T-cells isolated from gMLNwith and without HLA-G treatment after allogenic
intestinal transplantation. A) Representative gating strategy for recipient(LEW)-derived (MHC I/RT1.Ac-negative), CD45+ and CD8+ and
likewise, CD4+ T-cells. Percentages of CD4+ and CD8+ are given as percentages of CD45+ parent population, shown is a representative result for
CD8+ with and without HLA-G treatment at POD 7. (B) Overview of CD4+ and CD8+ T-cells with and without HLA-G treatment at both timepoints.
A significant increase in CD8+ T-cells in the CTL groups is shown without treatment, as well as a significant reduction of this CD8+ T-cell
population at day seven with HLA-G treatment.
doi:10.1371/journal.pone.0158907.g005
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Inflammation versus acute rejection
After intestinal transplantation, unspecific inflammation triggered by ischemia/reperfusion
injury and the transplant process, occurs in the grafts within hours after reperfusion is started.
These inflammatory processes impact on all compartments of the graft. The graft’s mucosal
integrity is temporarily compromised as well as graft motoric function and structural changes
in the graft tunica muscularis occur [22]. In this experiment, histologic grading of ACR using
the Wu-score clearly showed that the HLA-G treated animals suffered from less severe ACR
than untreated controls at both time points. The graft mucosal architecture was better pre-
served and crypt epithelial injury was less with HLA-G treatment as well as other morphologic
aspects specified by the Wu-score (see Fig 2A). Morphologically, a distinct leucotic cell infiltra-
tion both in the lamina propria and the graft mesentery was identified in the H/E stained allo-
graft specimens undergoing ACR as well a higher abundance of crypt apoptotic bodies,
especially seven days after transplantation. The increased rate of epithelial apoptosis associated
Fig 6. Gating strategy and overview of Treg (CD4
+/CD25+/FoxP3+) isolated from gMLNwith and without
HLA-G treatment after allogenic intestinal transplantation. (A) Gating strategy and representative result for
Treg analysis. (B) Overview of classical Treg (CD4+/CD25+/FoxP3+ Treg), isolated from gMLN. A tendency to
higher abundance in HLA-G treated animals, without reaching statistical significance (Mann-Whitney U test
p>0.05), was observed.
doi:10.1371/journal.pone.0158907.g006
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with rejection which was ameliorated by HLA-G treatment was confirmed using TdT-medi-
ated dUTP-biotin nick end labeling on POD 7 (see S1 Fig). Overall, these morphologic features
of ACR were markedly reduced in the groups treated with HLA-G.
Further analysis of graft whole mounts showed that a significant proportion of the
observed leucocytic infiltrate consisted of MPO+ cells (see Fig 3). In the early postoperative
phase, concomitant to the upregulation of inflammatory cytokines and chemotactic factors,
an influx of MPO+-mono- and granulocytes along with an activation of the resident muscu-
laris macrophages is a well described phenomenon in the graft muscularis [21]. Usually, these
inflammatory changes resolve after a few days in the rat ITX model, if isogenic strain combi-
nations (e.g. LEW->LEW) are used [23]. It is known that the mentioned MPO+ infiltrate cor-
relates with ischemia/reperfusion injury and graft inflammation shortly after isogenic ITX
and that this infiltrate intermittently resolves spontaneously. At day seven after allogenic ITX
however, a persisting MPO+ infiltrate correlates strongly with the ongoing graft destruction
caused by ACR [21]. In the allogenic model (BN->LEW) reported here, we likewise show the
transplantation related influx of MPO+ leucocytes in the graft tunica muscularis especially at
the early timepoint at day four and its persistence at the later timepoint at day 7 after allogenic
ITX (see Fig 3). While day four is still within the timeframe of the regularly observed inflam-
matory changes in graft muscularis specimens and is not affected by HLA-G treatment, the
MPO+ leucocytic infiltrate at POD seven must be largely attributed to ACR. Interestingly,
HLA-G treatment caused a significant reduction of MPO+ cell infiltration in the graft muscu-
laris at POD 7 (see Fig 3) possibly explaining the amelioration of ACR. Generally speaking,
myeloid cells (e.g. neutrophils, but also monocytes and macrophages) stain MPO+ in the Han-
ker-Yates reaction and are either directly or indirectly affected by HLA-G treatment according
to our data. Interestingly, the PIR-B inhibitory receptor which mediates HLA-G effects in the
murine model, has previously been reported to be expressed on these myeloid cells which
would support a direct interaction [24,25]. We indeed detected the Pir-B inhibitory receptor
mRNA in the graft mesenteric lymphnodes in our model (see S2 Fig). While the protective
effect of HLA-G at POD 7 can be explained by a reduced cell infiltration (of CD8+ cells and
MPO+ cells) the early effects are less obvious. At POD 4, the cellular components of the infil-
trate have not yet changed significantly, however the cytokine profile displays an early
Fig 7. ACR-related gene expression in graft muscularis. The first time point at four days after allogenic ITX showed a significant
downregulation of both TNFα and IL-10 by HLA-G treatment (Mann-Whitney U test p<0.05). At seven days after allogenic ITX, TNFα
expression remained significantly reduced by HLA-G treatment.
doi:10.1371/journal.pone.0158907.g007
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alteration with IL-10 and TNF-α downregulation. It could be assumed that the early tolero-
genic effect produced by the HLA-G treatment could be effected by altering the cytokine pro-
file of the cellular environment.
It is also known that ACR in intestinal allografts manifests itself not only histologically, but
also functionally by exhibiting reduced in-vitro contractility ([21]). Our data shows that the
observed histologic amelioration of ACR and reduced leucocytic cell infiltration by HLA-G
treatment was reflected in functional analyses of graft contractility: A corresponding preserva-
tion of graft motor function was found at POD seven with HLA-G treatment (see Fig 4).
ACRmediating T-cell populations
In the high-responder strain combination (BN->LEW) used for this study, a strong allore-
sponse results in severe ACR of the intestinal grafts without the use of immunosuppressive
agents. It has been an ongoing debate which cell type is mainly responsible for this alloresponse
in the setting of ITX. Both direct and indirect allorecognition play a role in intestinal transplan-
tation as the transplanted intestine is abundant in “passenger” lymphocytes and antigen pre-
senting cells (APCs). These donor-derived APCs can be directly recognized by- and in turn
activate- recipient-derived T-cells. Likewise, donor antigens are shed in the circulation and
reach the graft draining lymphnodes to be processed by recipient-derived APCs, which in turn
can activate donor-specific T-cells [26]. To add complexity, a bidirectional lymphocyte traffick-
ing to and from the grafted intestine, with recruitment of recipient monocytes, dendritic cells
and other immunocompetent cells into the graft and likewise migration of donor-derived lym-
phoid cells into recipient tissues has been described [27]. It is therefore logical that the trans-
planted intestine is highly immunogenic and exclusive depletion neither of the CD8+, or CD4+
T-cell compartment or sole blockage of costimulatory pathways can completely prevent rejec-
tion. However, it is widely accepted that mainly influxing recipient-derived CD8+ T-cells and
possibly NK cells cause ACR in this model [21,28,29]. Even though the rejection process may
not be exclusively mediated by recipient-derived CD8+ T-cells [30], this population is widely
accepted to play a major role in ACR [31]. From our data, we can now confirm that recipient-
derived CD8+ T-cells are recruited into the gMLN in rising numbers as ACR progresses (CD8+
in group CTL 7d> CD8+ in group CTL 4), see Fig 5B. Furthermore, HLA-G itself is known to
act a) via triggering CD8+ T-cell apoptosis by direct interaction with the CD8 T-cell receptor
and activating the Fas/FasL pathway [9,10] and b) via tolerization of dendritic cells, leading to
allogenic hyporesponsiveness and possibly to Treg-induction [14]. We therefore postulated that
HLA-G should ultimately exhibit its tolerogenic characteristics by downregulation of the recip-
ient-derived CD8+ T-cell population. We can now confirm this hypothesis in our model, as a
significant downregulation of recipient-derived CD8+ T-cells was found with HLA-G treat-
ment (CD8+ in group HLA-G 7d< CD8+ in group CTL 7d), see Fig 5A/5B. This reduction of
recipient-derived CD 8+ T-cells was also clinically important because it correlated with amelio-
rated ACR, but whether this stemmed from induction of apoptosis in these T-cells or rather
from a failure of T-cell activation/expansion due to HLA-G treatment (as has been described in
vitro [32]), is still unclear at this point. Referring to a postulated Treg-induction, we could not
prove an induction of the classical CD4+/CD25+/FoxP3+ Treg population, (see Fig 6). Possible
reasons for this failure to detect a significant Treg induction is the scarcity of this T-reg subpop-
ulation which may make it hard to detect in this in-vivo model. Another possibility would be
that the phenotype of Treg resulting from interaction with HLA-G (or from interaction with
DCs exposed to HLA-G) may differ from the classical CD4+/CD25+/FoxP3+ Treg phenotype, as
HLA-G is known to also induce Tr1 cells and CD4low/CD8low Treg independent of FoxP3
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expression [33]. Thus, Treg induction cannot be ruled out as a potential mechanism of action
from our data and further research is warranted.
Limitations of the study
A significant immunosuppressive effect of HLA-G treatment was seen in this model of experi-
mental intestinal transplantation but it failed to completely resolve ACR. Arguably, a full
tolerization was not expected in this high responder rat model without any classical immuno-
suppression given the high immunogenicity of the transplanted intestine. On the other hand,
this high immunogenicity makes the intestine an interesting solid organ to study the effects of
novel immunomodulatory drugs and biologicals as potential effects can be studied histologi-
cally and functionally in a sensitive system. Furthermore, although a significant effect on the
recipient-derived CD8+ T-cell population was demonstrated, it is not deducible from our study
whether this was due to induced T-cell apoptosis or failure of expansion/activation. Clearly fur-
ther studies are needed to elucidate the mechanism of action of HLA-G in this model.
Relevance of novel immunomodulatory strategies in intestinal
transplantation
In the current era, only 60% of intestinal grafts remain functional after 4 years and chronic
rejection is experienced by up to 20% of patients despite the ongoing advances in immunosup-
pressive therapy [34]. Historic approaches to achieve prope tolerance as well as modern immu-
nosuppressive regimens based on monoclonal (anti-CD 25, anti-CD3, anti-CD52) or
polyvalent (ATG, ALG) depleting antibodies combined with calcineurin inhibitors have not
solved the problem of acute and especially chronic rejection. Until recently it was not feasible
to test the tolerogenic potential of HLA-G paralogues in vivo. This has changed with the devel-
opment of HLA-G fusion proteins such as the ß2-microglobulin fused to the HLA-G 5 heavy
chain as described in [13] and [35]. Since the tolerogenic potential of HLA-G can now be
explored for solid organ transplant research, this potentially creates new options for immuno-
modulation: Firstly, in combination with classical immunosuppression in order to achieve long
term stable graft function and avoid chronic rejection and secondly, to minimize calcineurin-
inhibitor-related toxicity and its long term adverse effects.
Conclusion
This proof-of-principle study in an experimental model of orthotopic, allogenic intestinal
transplantation demonstrates the immunoprotective effect of a recombinant HLA-G fusion
protein for the first time in a solid organ transplant model. We show that HLA-G acts either
directly or indirectly on an ACR-related and recipient-derived CD8+ T-cell population. Further
studies on the in-vivo effects of HLA-G on T-cells, dendritic cells and Treg subpopulations in
the setting of acute and chronic rejection after solid organ transplantation are warranted.
Supporting Information
S1 Fig. TUNEL staining for detection of intestinal epithelial apoptosis. An increased rate of
intestinal intraepithelial apoptosis was associated with rejection as detected using TdT-medi-
ated dUTP-biotin nick end labeling with FITC immunofluorescence. In each animal, 5 random
high power fields (20x) were chosen and intraepithelial apoptotic signals per 10 consecutive
crypts were counted. HLA-G treatment showed significant reduction of intraepithelial apopto-
sis after 7 days (Mann-Whitney U test p<0,05).
(TIF)
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S2 Fig. Detection of the Pir-B receptor in the gMLN. In all 4 representative animals tested
(triplicate tests), the presence of the specific Pirb receptor mRNA was detected in mRNA isolates
from the gMLN using a specific probe for a 77bp amplicon as described above and in (36).
(TIF)
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